A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
A2 Biotherapeutics Inc.
Study ID
NCT06885424
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No additional intervention administered in this long term follow-up study — OTHER
    Safety follow-up for A2 Bio GT products administered in a previous interventional study

Study Details

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Key Dates

Start date
Jul 31, 2025
Status verified
May 2026
Primary completion
Mar 31, 2030
Completion
Mar 31, 2040

Study Design

Enrollment
400 participants (estimated)

Arms

  • Arm: Participants that received A2 Bio GT products

Primary Outcome Measure

Long-term safety of previous A2 Bio GT treatment [ Time Frame: 15 years post treatment with A2 Bio GT product ]

Locations (3)

FacilityCityStateZIPSite coordinators
Banner HealthGilbertArizona85234-
Mayo ClinicRochesterMinnesota55905-
NYU Langone Medical CenterNew YorkNew York10016-

Find similar trials in Gilbert, AZ

By condition
Colorectal cancerHead and neck cancerLung cancerOvarian cancerPancreatic cancer
By specialty
OncologyGI oncologyENTLung oncologyLung diseaseGynecologic oncologyWomen's health
By research site
Banner Health· Gilbert, AZMayo Clinic· Rochester, MNNYU Langone Medical Center· New York, NY

Related Studies